Rik Schoemaker

Rik Schoemaker, founder, owner, and senior consultant at Occams, is a highly respected expert in the field of pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation. With a robust background in biology and theoretical biology from the Free University of Amsterdam, Rik has dedicated his career to advancing quantitative methods in clinical pharmacology and drug development. At Occams, he leads a team of specialists providing tailored PK/PD modelling solutions that support decision-making throughout the drug development lifecycle, from early-phase studies to regulatory submissions.

Currently, Rik's role involves overseeing complex modelling projects that optimize dose selection, support clinical trial design, and facilitate regulatory interactions with agencies such as the EMA and FDA. His expertise extends to developing innovative tools that automate report generation, significantly improving efficiency and consistency in pharmacometric analyses. Rik’s deep understanding of clinical pharmacology, combined with his proficiency in statistical software such as SAS and R, enables him to deliver robust, scientifically sound models that inform critical development decisions.

Among his key projects are the development of population PK/PD models for novel therapeutics, where he integrates clinical data with mechanistic insights to predict drug behavior and response. Rik also collaborates closely with pharmaceutical clients to refine study protocols and interpret complex datasets, ensuring that pharmacometric insights translate into tangible clinical benefits. His comprehensive skill set, encompassing biostatistics, clinical trial design, and advanced modelling techniques, positions him as a trusted partner in the industry, continuously pushing the boundaries of pharmacometric innovation to accelerate the delivery of safe and effective medicines.